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Alzheimer’s disease (AD) is an age-related neurodegenerative disorder characterized
by progressive anterograde amnesia, cerebral atrophy, and eventual death. Current
treatment has limited efficacy and cannot decelerate the disease progression. Clinical
trials targeting the removal of the neuropathological hallmarks of AD, including accu-
mulation of amyloid plaques or neurofibrillary tangles, have failed to modify disease
progression. Without new or innovative hypotheses, AD is poised to become a public
health crisis within this decade. We present an alternative hypothesis—that AD is the
result of multiple interrelated causalities. The intention of this manuscript is to initiate
a discussion regarding these multiple causalities and their overlapping similarities.
The idea of creating subgroups allows for better identification of biomarkers across
a narrower patient population for improved pharmacotherapeutic opportunities. The
interrelatedness ofmany of these proposed subgroups indicates the complexity of this
disorder. However, it also supports that no one single factor may initiate the cascade
of events.
KEYWORDS
cellular senescence, hyperexcitable neuronal networks, metabolic syndrome, mitochondrial cas-
cade hypothesis, sleep disturbances, traumatic brain injury, two-hit vascular hypothesis
1 INTRODUCTION
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder
characterized by progressive anterograde amnesia, neuronal loss,
cerebral atrophy, and eventual death. Currently AD is the sixth leading
cause of death in the United States, with an estimated 5.8 million
Americans diagnosed, posing a severe socioeconomic impact. Available
pharmacotherapeutic options target cholinesterase inhibitors and
partial antagonism of the N-methyl-D-aspartate (NMDA) receptors;
these treatments have limited efficacy, are symptomatic, and do not
decelerate disease progression. Despite decades of attempted clinical
trials to bring novel, disease-modifying compounds to market, AD
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continues to be incurable and teeters on the precipice of becoming a
public health disaster.
The primary neuropathological hallmarks of AD include extracellu-
lar plaques composed of aggregated amyloid beta (Aβ) and intracellular
neurofibrillary tangles formed from hyperphosphorylated tau protein.
To date, these biomarkers are used to indicate disease progression and
post-mortem AD confirmation. However, there is ongoing debate as
to which proteinopathy precipitates the neuropathological changes
that culminate in clinical manifestation of dementia and AD diagnosis.
Arguments for Aβ, tauopathies, and synergistic effects have been
proposed as the underlying mechanism that initiates the pathological
chain reaction of events. However, clinical trials designed to target
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various mechanisms involved in accumulation and aggregation of
these misfolded proteins have been unsuccessful at slowing disease
progression. These failures are attributed to multiple factors including
poor trial design, entry criteria, retention rates, clinical endpoints, and
disease stage selection.1 After all, what good is clearing the brain of
misfolded proteins if neuronal damage is already too pronounced to
have a pro-cognitive impact? This has driven the need to reclassify
AD based on available cerebral spinal fluid (CSF) and neuroimaging
biomarkers for earlier diagnosis,2 with the hopes of providing better
therapeutic outcomes.
The inability to find a biomarker (or multiple biomarkers) that accu-
rately predicts disease manifestation may be flawed due to the comor-
bidity of the disease. This article presents an alternative hypothesis
regarding our initial presumptions of AD. That multiple, yet potentially
overlapping, causalities contribute to the neuropathological changes,
which trigger the cognitive and functional decline observed in AD. This
article is intended to start discussion of the major individualistic com-
ponents rather than an exhaustive criterion or description of each pos-
sible subgroup. Eventually, large data set analysis will be needed from
already existing databases (including the World Wide AD Neuroimag-
ing Initiative, National Institute on Aging Genetics of ADData Storage,
National Alzheimer’s Coordinating Center, and the Global Alzheimer’s
Association Interactive Network, to name a few) for identification and
confirmation of novel subgroups in amanner similar to recent research
into diabetes.3 Neuropathological variation already indicates multi-
ple comorbidities exist that may mimic AD. However, thorough clini-
cal and epidemiological analysis can elucidate subgroups or even dis-
tinct disease states such as Limbic-Predominant Age-Related TDP-43
Encephalopathy. Creating subgroups allows for better identification
of biomarkers across a narrower patient population for individualized
treatment regimens.
1.1 Genetic subgroups
1.1.1 Early onset genetic subgroups for AD
Age is the primary risk factor for developing AD, with 65 years of age
is designated as the cutoff that defines early onset AD (EOAD) ver-
sus late-onset AD (LOAD). Current estimates indicate that 2% to 10%
of all AD cases are EOAD and that these patients first present with
observable symptoms between 30 and 65 years or age.4 In addition to
memory impairments, these EOAD patients also include non-cognitive
symptoms such as aphasia and visual dysfunctions. Genetic studies of
patientswith EOADhave identified several autosomal dominantmuta-
tions including amyloid precursor protein (APP), presenilin 1 (PSEN1),
and presenilin 2 (PSEN2). Normal, non-amyloidogenic APP process-
ing occurs by sequential cleavage of β- then γ-secretase resulting in
Aβ peptide of up to 40 base pairs in length. Mutations in PSEN1 or
PSEN2, the catalytic region of γ-secretase, creates Aβ peptides with
42 residues.4 Referred to as the amyloidogenic pathway, these longer
Aβ peptides are prone to aggregation that is responsible for the diffuse
neuritic plaques observed in AD. Identification of these mutations has
RESEARCH INCONTEXT
1. Systematic review: The authors reviewed the literature
using PubMed and Google Scholar. Although genetic and
environmental risk factors for Alzheimer’s disease (AD)
are well explored in the literature, to-date, no disease-
modifying therapies have been developed. This has led
the authors to discuss these in terms of individual, but
potentially overlapping, causalities that trigger the cog-
nitive and functional decline observed in AD. All relevant
citations are appropriately cited.
2. Interpretation: Our article serves as a discussion for
elucidating AD subtypes based on environmental fac-
tors such as blood-brain barrier disruption, metabolic
syndrome, mitochondrial dysfunction, traumatic brain
injury, hyperactive neuronal networks, cellular senes-
cence, sleep disturbances, and microbial infiltration in
conjunction with the involvement of early and late-onset
AD genes.
3. Future directions: Creating AD subgroups allows for
biomarker identification across a narrower patient popu-
lation for improved pharmacotherapeutic opportunities.
The interrelatedness of many of these proposed sub-
groups indicates combination therapeutic approaches are
warranted.
significantly enhanced our understanding of AD leading to the amyloid
cascade hypothesis, which states that Aβ accumulation causes synap-
tic dysfunction, formation of neurofibrillary tangles from hyperphos-
phorylated tau protein, and neuronal loss. However, these autosomal
dominant mutations may account for only a small percentage of EOAD
cases, with unidentified autosomal recessive traits accounting for the
remainder.
1.1.2 Late-onset genetic subgroups for AD
Recent genome-wide association studies (GWASs) have identified at
least 21 genetic loci that increase the risk for LOAD.5 However, for
a majority of these loci, the biological importance with regard to dis-
ease pathogenesis is relatively unknown. As such, this article focuses
on genes that have establishedmechanisms contributing to LOAD.
1.1.3 Apolipoprotein E
Apolipoprotein E (apoE) is a glycoprotein involved in cholesterol trans-
port, the gene of which in humans exists as three polymorphic alleles
(ε2, ε3, and ε4). TheAPOE ε4allele is themajor genewith semi-dominant
inheritance that increases the odds ratio of developing AD throughout
an individual’s lifetime. This gene is the second biggest risk factor
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for developing AD, only behind aging, and has sex (female > male)
and copy number (homozygous > heterozygous) attributes. Although
APOE ε4 is also associated with EOAD, this is at a much lower ratio
than in individuals older than 60 years of age and observed more
frequently in patients who have a positive family history of AD.
Several mechanisms explain this increased incidence of AD. In the
central nervous system (CNS), apoE is the primary protein respon-
sible for triglyceride and cholesterol transport, which is necessary
for maintaining the lipid membranes of nervous tissue as well as
axonal myelination. The APOE ε4 allele is less efficient at transport-
ing these fatty acids, thereby altering glucose transporter function
leading to metabolic dysregulation.6 In addition, apoE is an Aβ
chaperone, but the isoforms differ in their binding affinities. The APOE
ε2 and ε3 alleles facilitate Aβ clearance across the blood–brain barrier
(BBB) through low-density lipoprotein receptor-related protein 1
(LRP1), whereas the ε4 facilitates oligomerization and deposition
rather than clearance.7 With regard to tau pathology, apoE ε3 binding
can prevent hyperphosphorylation, unlike ε4 carriers that have higher
total tau, phosphorylated tau, and tau/Aβ42 ratios. Thesemultifactorial
phenotypes may confer synergistic effects that are detrimental over
time.
1.1.4 Translocase of outer mitochondrial
membrane 40
Translocase of outer mitochondrial membrane 40 (TOMM40) gene is
in linkage disequilibrium with APOE. A poly-T polymorphism at intron
6 of the TOMM40 gene is associated with increased risk and onset
of AD that is APOE-independent.8 However, others have shown that
TOMM40 poly-T associations with LOAD-related phenotypes are a
result of single nucleotide polymorphisms of the APOE allele located
in proximity to the TOMM40 gene on chromosome 19.9 These dis-
parate findings may be due to the length of the Poly-T polymorphism,
the AD phenotype being assessed, and the individual’s age at the time
of assessment. This gene codes for the Tom40 protein essential for
translocation of nuclear-encoded proteins into the mitochondria. This
results in mitochondrial dysfunction, oxidative stress, and bioenerget-
ics deficits that cause apoptotic cell death.
1.1.5 Triggering receptors expressed on
myeloid cells
Triggering receptors expressed on myeloid cells (TREMs) are trans-
membrane glycoproteins responsible for regulation of innate immune
resistance. TREM2 homozygous loss-of-function mutations are
associated Nasu-Hakola disease, which is characterized by osteo-
clast abnormalities and dementia. In addition, genomic sequencing
of AD patients indicates that heterozygous TREM2 mutations are
risk factors for LOAD.10 In the CNS, Trem2 is exclusively found on
microglia and binds lipoproteins, Aβ, and apoE with similar affinities
for all three isoforms.11 Activation of the TREM2 receptor results in
anti-inflammatory responses by suppressing tumor necrosis factor
(TNF) and interleukin (IL)-6.12 Arginine-to-histidine TREM2 point-
mutation variants lead to impaired phospholipid binding, Aβ plaque
accumulation, tau hyperphosphorylation, neuroinflammation, and
neuronal damage indicating propermicroglial function is important for
preventing AD pathology.
1.2 Environmental subgroups
1.2.1 Traumatic brain injury (TBI)
TBI is the result of a sudden impact to the head causing damage to the
brain and potentially loss of consciousness (LOC). Motor vehicle acci-
dents, sports, combat zone injuries, and falls are themajor contributors
to TBI, which commonly involve the frontal and temporal lobes.13 The
pathobiology of TBI is often divided into focal or diffuse injuries; how-
ever, most moderate and severe insults involve combinatorial effects.
The initial insult results in edema and swelling, followed by ischemia,
excitotoxicity, and reactive gliosis that triggers numerous apoptotic
and necrotic cellular pathways leading to neuronal loss.13 But, despite
thenumerousdocumentedoccurrencesofTBI, clinical studies toexam-
ine this causal relationship for later-life dementia have produced dis-
cordant results. Several studies support a history of TBI contributing
to dementia and AD later in life,14 whereas others have shown no
association.15 However, methodological considerations, such as incon-
sistent reporting of TBI severity and self-reported LOCmayundermine
theADpredictive value of these findings. Additional factors such as the
numberof injuries, inter-injury interval, and ageof occurrencemayalso
increase the dementia risk,16 while adding to the complexity of inter-
preting the results.
The complexityofTBImayaccount for several differentmechanisms
associated with AD development. Neuronal loss is believed to under-
lie the long-term effects on cognitive dysfunction andworse functional
outcome in the geriatric population.17 Individuals with a genetic pre-
disposition for AD may experience a synergistic effect from TBI. For
example, individuals with the APOE ε4 allele and a history of TBI had a
significantly increased risk for developing AD compared to those with-
out head injuries,18 thereby supporting a reduced resiliency. Because
the ε4 allele is not as efficient at transporting lipids and triglycerides,
axonal remyelination would be reduced following TBI, which may initi-
ate long-term neurodegenerative processes, and the susceptibility of
tau and amyloid accumulation in ε4 genotypes may potentiate these
effects.
Athletic sports with the potential for repeated head trauma are
known to develop adverse cerebral proteinopathies, including neu-
rofibrillary tangles (and occasionally amyloid plaques), in what has now
been documented as chronic traumatic encephalopathy. These pro-
teinopathies have also been observed throughout the brain, years after
a single incidence of TBI.19 Although themechanism for this accumula-
tion is the subject of intense research, the damaged axonsmay provide
a chronic source formisfolded proteins. APP is known to accumulate in
degenerating axons, whereas tau hyperphosphorylation could be the
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result of mechanical stress on microtubules.20 Overtime, the diffuse
deposition patterns could be attributed to prion-like spread of these
proteinopathies.21
BBB damage after TBI causes acute and long-term cerebrovascu-
lar dysfunction that may also be a precipitating factor in the etiol-
ogy of AD. Oligomeric Aβ and hyperphosphorylated tau have been
found surrounding damaged cerebralmicrovessels in post-mortemTBI
patients.22 The reasons for this accumulation are largely unknown, but
the damaged microvasculature may prevent adequate clearance.23 In
addition, amyloid and/or tau accumulation have been shown to disrupt
the neurovascular unit (discussed below) independent of TBI. A feed-
forward mechanism might result whereby accumulation of misfolded
proteins surrounding damaged microvasculature cause further deteri-
oration and aggregation.23 Regardless, further research is needed to
elucidate the causality of TBI on initiation of dementia and AD.
1.2.2 Blood–brain barrier disruption
The neurovascular unit of the BBB is composed of smooth mus-
cle and endothelial cells, astrocytic end feet, neurons, and pericytes
that form gap and tight junctions to create a semipermeable mem-
brane. This membrane maintains the CNS extracellular fluid while
preventing neurotoxic compounds and microbial agents from enter-
ing the CNS through the bloodstream, which also adds to the com-
plexity of designing CNS therapeutics. Selective transport of essen-
tial macromolecules (glucose, cholesterol, etc) occurs by transcyto-
sis that maintains neurovascular coupling, hemodynamic responses to
support energy demands during neuronal activity. Aging is associated
with a modest decline in cerebral blood flow and BBB breakdown to
the limbic and associative cortices.24 This gradual cerebral hypoper-
fusion reduces the supply of energy substrates that are important for
maintaining these neuronal networks25 while simultaneously impair-
ing clearance of neurotoxic proteinopathies. Not surprisingly, vascular
dysfunction is observed innumerousneurodegenerativedisorders, and
may be the instigating factor precipitating AD progression.
Neuronal activity and the subsequent metabolic demands regulate
cerebral blood flow. IndividualswithMCIorADdisplay resting cerebral
hypoperfusion that gradually progresseswith disease severity andmay
be present before overt signs of cognitive decline.26 In mouse models
of ADpathology, transient hypoperfusion causes long-lasting increases
to tau hyperphosphorylation and enhanced expression of β-secretase
that causes elevated amyloid levels.27 Imaging studies in humans, how-
ever, support a role for amyloid deposition, causing rather than being a
result of cerebral hypoperfusion. The level of amyloid deposition was
associated with cerebral blood flow reductions that progressed as a
function of disease severity.28 Accordingly, those with genetic risk fac-
tors associated with amyloid accumulation may be at a greater risk
for vascular abnormalities. The limited clinical studies warrant further
investigation.
Disruption of the BBB increases vascular permeability and hypop-
erfusion, resulting in perturbed neurovascular coupling.29 Decline of
BBB integrity is observed in the aging hippocampus first, which ismore
pronounced in cognitively impaired individuals and before neuronal
atrophy.24 Pericyte loss is a contributing factor to BBBbreakdown that
has been observed in both MCI24 and AD post-mortem tissue. This
allows blood-derived neurotoxic species including hemoglobin, plas-
min, thrombin, and fibrin to enter the CNS, causing vascular-mediated
secondary neuronal degeneration. Vascular damage also reduces Aβ
clearance from the interstitial fluid through LRP1, which subsequently
amplifies pericyte loss and microvasculature lesions.30 The accumula-
tion of amyloid deposits along cerebral microvasculature, called cere-
bral amyloid angiopathy, is a pathological feature of AD and is believed
to exacerbate cognitive decline.31 The combination of amyloid accu-
mulation and pericyte loss causes tau hyperphosphorylation and sub-
sequent neuronal damage.30
In addition, the underlying vascular similarities of several midlife
AD risk factors (obesity, hypertension, and diabetes) have led to the
two-hit vascular hypothesis of AD.32 Based on this hypothesis, vas-
cular risk factors (hit 1) cause BBB disruption, hypoperfusion, and
decreased neurovascular coupling, leading to early neuronal dysfunc-
tion. The resulting increase in amyloid accumulation (hit 2) propagates
AD progression by aggravating BBB dysfunction, accelerating amyloid
and tau deposition, and amplifying the neurodegeneration and subse-
quent cognitive decline.
1.2.3 Metabolic syndrome and insulin resistance
Metabolic syndrome (MetS) refers to multiple metabolic disturbances
including hyperglycemia, hypercholestrolemia, dyslipidemia, adiposity,
and insulin resistance,which increase the risk of cardiovascular disease
and type2diabetesmellitus (T2DM).Over the past several decades the
prevalence of MetS has risen steadily throughout the United States.
These metabolic dysregulations are often attributed to overnutrition
and sedentary lifestyles. Furthermore, the natural decline of basal
metabolic rate, compounded with lifestyle choices, increases the inci-
dence of MetS during aging. More than half of all adults 70 years of
age or older meet the criteria for this disorder.33 Although the vascu-
lar risk factors associated with MetS and their contribution to AD eti-
ology has been discussed previously, insulin resistance is hypothesized
to be a separate contributor to disease initiation. The co-morbidity
of vascular and insulin signaling pathways in MetS makes it difficult
to discriminate their causal effects on AD pathogenesis because both
are linked to hippocampal dysfunction. However, imaging analysis sup-
ports region-specific effects, whereby the dentate gyrus is vulnerable
to hypoglycemia related to insulin resistance, but the CA1 and subicu-
lum show more dysfunction from hypoperfusion related to vascular
abnormalities.34
Observational, longitudinal, and prospective studies have shown
that insulin resistance and T2DM during midlife are associated with
an increased risk for developing dementia and AD later in life.16 And
recently, a genetic association between fasting glucose, insulin lev-
els, and AD has been demonstrated.35 Insulin, and the structurally
analogous insulin-like growth factor 1, are locally produced in the
brain where they can act upon their corresponding receptors located
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throughout the cortex, hippocampus, and hypothalamus. Receptor
activation has been shown to regulate glucose uptake, promote
synaptic plasticity, improve cognition, and modulate pro-inflammatory
cytokines that are important for healthy aging. Conversely, impaired
insulin signaling accelerates aging and has been demonstrated in the
hippocampus of AD patients. Based on this cerebral insulin resistance,
some groups have postulated that AD is a third subtype of diabetes.36
Through separate pathways, insulin resistance causes accumula-
tion of both amyloid and tau pathology. Insulin signaling promotes
nonamyloidogenic processing of APP while subsequently increas-
ing insulin degrading enzyme (IDE) that cleaves Aβ. But dysfunc-
tional insulin signaling promotes amyloid accumulation by decreas-
ing both the expression of IDE and its affinity to cleave monomeric
Aβ42,37 causing its aggregation and accumulation. Furthermore, insulin
resistance increases tau hyperphosphorylation through activation of
glycogen synthase kinase 3β and inhibition of AMP-activated pro-
tein kinase-mediated tau dephosphorylation. Hyperphosphorylated
tau also aggravates insulin resistance by accumulating insulin as insolu-
ble oligomers inside neurons.38 Accumulation of these proteinopathies
increases glial pro-inflammatory cytokines (TNFα, IL-6, and IL-1β),
which cause phosphorylation of serine on insulin receptor substrate
1, blocking insulin signaling.39 Furthermore, peripheral inflammation
caused by adiposity can exacerbate pro-inflammatory cytokines that
can readily cross the BBB irrespective of its integrity having been com-
promised by vascular risk factors. This creates a vicious feed-forward
cycle propagating AD pathology and neurodegeneration.
In addition to propagating AD pathology, cerebral insulin insensitiv-
ity alters glucose metabolism. Compared to cognitively normal control
patients, post-mortem analysis of AD patients have reduced glycolytic
flux despite elevated glucose levels in CNS tissue.40 Several factors
may contribute to the elevated glucose levels including reduced
glucose transporter surface expression,40 defective insulin receptor
signaling, and reduced CNS insulin levels.39 Irrespective of the mode
of resistance, the overall net effect is reduced utilization of available
energy substrates that decreases mitochondrial bioenergetics, which
are important for maintaining functional neuronal networks. Selective
CNS insulin increases can be achieved by intranasal delivery, which has
pro-cognitive effects in healthy, MCI, and AD patients that may also
attenuate classical AD proteinopathies.41
1.2.4 Mitochondrial-bioenergetic deficits
Mitochondrial organelles maintain numerous cellular functions that
are critical for healthy aging, including energy metabolism, calcium
homeostasis, apoptosis, lipid metabolism, redox signaling, stem cell
fate, and cellular senescence. These processes can vary across cell
type. Although astrocytes utilize glycolytic pathways to produce
adenosine triphosphate (ATP), neurons rely heavily on oxidative
phosphorylation for its generation to help maintain neurotransmitter
synthesis and uptake, resting membrane potential, and synaptic
plasticity. A byproduct of oxidative phosphorylation is the formation
of reactive oxygen species (ROS), the levels of which are modulated by
antioxidant mechanisms. At low concentrations, ROS is important for
synaptic plasticity involved with memory formation and consolidation,
but excessive production of ROS can lead to oxidative stress and lipid
peroxidation that can develop into pathological conditions.
The metabolic demands placed upon neuronal networks are a rea-
son why the brain utilizes 20% to 25% of total body glucose. A gradual
decline in cerebral energy utilization with an increase in chronic oxida-
tive stress is observed with normal aging.42 However, neuroimaging
with [18F]fluorodeoxyglucose positron emission tomography (FDG-
PET) indicates that hypometabolism is worse in AD patients compared
to age-matched controls, is observable before cognitive deficits, and
is a sensitive measurement of AD progression.43 Multiple factors can
contribute to cerebral hypometabolism including reduced glucose
transporter number or function, BBB disruption, and/or mitochondrial
dysfunction, which makes elucidating the primary cause difficult.
However, a maternal family history of AD predisposes individuals to
hypometabolism as indicated by FDG-PET.44 Because mitochondrial
DNA is passed along maternally, this supports a primary role for
mitochondrial dysfunction as the instigating process in AD, which has
been coined the “mitochondrial cascade hypothesis.”45 For example,
ATP can both prevent protein aggregation and dissolve previously
formed aggregates.46 The aggregation of amyloid and tau may be
linked directly to decreased ATP production as a result of mitochon-
drial dysfunction. Mitochondrial import receptors can interact with
misfolded protein aggregates, leading to their subsequent import
and degradation by proteases.47 A decline in mitochondrial function
would prevent protease degradation and lead to the accumulation and
aggregation of misfolded proteins observed in AD.
These mitochondrial disruptions may initially occur at the level of
individual neurons or synapses before more global effects occur. A
neuron with impaired mitochondria has reduced energy production
and may up-regulate oxidative phosphorylation as a compensatory
mechanism in a process referred to as the inverse Warburg effect.48
This “unhealthy” neuron pulls additional energy substrates (glucose
and lactate) from the surrounding glia, while simultaneously increas-
ing the production of ROS. These two factors cause nutrient deple-
tion and oxidant stress in “healthy” neurons, thereby leading to addi-
tional mitochondrial dysfunction that precipitates their conversion to
an unhealthy phenotype. Over time, this can cause neuronal loss and
lead to the cognitive impairments observed inAD.Because this process
is postulated to begin with individual mitochondrial deficits, it has not
been tested experimentally.
1.2.5 Hyperactive neuronal networks
One of the earliest preclinical symptoms associated with AD is hip-
pocampal epileptiform discharges indicative of hyperactive neuronal
networks.49 Thesehyperactiveneuronal networkshavebeenobserved
years prior to onset of cognitive impairment and can progress in sever-
ity with accumulation of either Aβ or tau.50 However, it is uncertain if
these effects are dependent upon abnormal AD-specific protein accu-
mulation or contribute to spreading the pathology. Endogenous Aβ
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was shown to increase the release probability at excitatory synapses51
as well as stimulate synaptic glutamate release.52 But, transsynaptic
signaling has also been implicated in the spreading of both tau and
Aβ pathologies.21 In addition, hyperactive neuronal networks require
considerably more energy substrates for ATP production to maintain
both neurotransmitter synthesis and the resting membrane poten-
tial. To maintain the energy substrates, focal changes in blood flow
surrounding the hyperexcitable neuronal networks are required that
results in alterations to neurovascular coupling and has the potential
to propagate seizure activity into other cortical areas.
The underlying cause of the hyperactive neuronal networks could
be attributed to excitatory/inhibitory imbalance that can cause mem-
ory impairments with age.53 Either an increase in the amount of
glutamate, a decrease in γ-aminobutyric acid, or both, would result in a
net overall increase in local environments of tonic levels of glutamate.
These increased tonic levels of glutamate are thought to underlie
the initial onset of cognitive impairment because the persistent acti-
vation at postsynaptic receptors dampens physiologically relevant
signaling.54 As such, this may explain why memantine, a partial NMDA
antagonist, has shown pro-cognitive effects in AD patients. Over time,
if this excitatory/inhibitory imbalance is not corrected, glutamate
levels may cross a threshold and become excitotoxic and contribute to
neuronal loss, cortical atrophy, cognitive decline, and eventual death.
1.2.6 Cellular senescence
Cellular senescence is characterized by a permanently arrested cell
cycle that is no longer responsive to differentiation and apoptotic
signaling processes, yet are still metabolically active. Senescent cells
accumulate in multiple mitotic tissue types as a result of various
stressors, and they have become a hallmark response of natural aging.
Once cells undergo senescence, they begin to secrete numerous
pro-inflammatory cytokines and chemokines in a process referred to
as senescence-associated secretory phenotype, which has additional
deleterious consequences in both neighboring and remote cells.
Because cellular senescence is a result of the aging process, this has
led to the hypothesis of a causative nature in AD. Because neurons
exist in a post-mitotic state, it is difficult to definitively determine
if they can undergo a senescent phenotype. However, other cell
types that are essential for supporting neuronal function can become
senescent. Astroglia, important for regulating synaptic transmission,
BBB integrity, and neuronal metabolism, accumulate in the aged brain
and in higher abundance in the brains of patients with AD. Senescent
astrocytes have reduced expression of excitatory amino acid trans-
porters, resulting in decreased synaptic glutamate clearance.55 The
reduced glutamate clearance can cause hyperexcitable neuronal net-
works that may, over time, create an excitotoxic environment leading
to neuronal atrophy. In addition, oligodendroglial progenitor cells,
which are responsible for myelinating neuronal axons, also undergo
senescent phenotypes in AD brains, particularly surrounding amyloid
plaques.56 Insufficient myelination reduces the membrane resis-
tance, thereby leading to loss of action potential velocity. This would
particularly impact the CA1 pyramidal neurons and could underlie the
initial anterograde amnesia observed in AD. A better understanding
and interpretation of CNS senescent cell types and their resulting
phenotypes will help to elucidate a role in AD.
1.2.7 Microbial infiltration
An infectious origin to the etiology of AD has been marred with con-
flicting results. Previous post-mortem analysis of AD CNS tissue does
not indicate a microbial connection. But more recent data support
the presence of viral, bacterial, and fungal microbes in post-mortem
brain tissue of AD patients.57 These discrepant findings are oftentimes
attributed to methodological considerations, including tissue region
analyzed and fixed vs frozen preservation methods, with the latter
providing higher quality DNA samples. The strongest microbial case
involves herpes simplex virus type 1 (HSV1) in combination with APOE
ε4 carriers.58 Meta-analysis between spirochetal bacteria or Chlamy-
dophila pneumoniae indicates a respective 10- and 5-fold increased
association with AD brains compared to control brains.59 At present,
though, more questions than answers exist, including route of infil-
tration and active residence. As mentioned previously, disruptions of
the brain microvasculature enable toxic cells and microbial agents to
enter the brain causing inflammatory and immune responses that ini-
tiate neurodegenerative processes. Although these microbial species
have also been observed in the blood, it is unknown if they actively par-
ticipate to BBB deterioration. Once inside the CNS, are thesemicrobes
dormant or active participants in known AD pathology? Because the
majority of microbes are associated with amyloid plaques,57,58 this
may support an active role in facilitating amyloid accumulation. Even
if microbes take up dormant CNS residence, their potential to chroni-
cally activate pro-inflammatory cytokines can have deleterious effects
on pathobiology. Regardless, more research is needed to elucidate a
potential microbial cause to initiating AD pathology, particularly given
the neurological manifestations in patients infected with severe acute
respiratory syndrome coronavirus 2.60
1.2.8 Sleep disturbances
Over the past several decades, the number of adults and children
experiencing chronic sleep insufficiency is steadily rising and has been
attributed to increased working and screen time hours. Quality sleep
aids in memory consolidation, whereas sleep deprivation is known to
reduce cognitive performance and increase the risk for developing
MetS. Severalmeta-analyses link disrupted sleep patterns to the devel-
opment of cognitive decline and AD.61 In particular, sleep-disordered
breathing and insomnia have been shown to predict cognitive decline
and may serve as a potential biomarker.62 Restful sleep increases
the interstitial space, allowing for clearance of cellular activity waste
products through CSF exchange referred to as the glymphatic system.
Even a single night of sleep deprivation can cause Aβ accumulation.63
Furthermore, sleep disturbances can limit CSF transfer of apoE into
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the brain to help maintain axonal myelination, synaptic plasticity, and
cognition.64 However, a better understanding is needed to determine
whether sleep disturbances contribute to or is a result of dementia.
1.3 Methods to refine AD subgroups
The majority of individuals diagnosed with AD present to a general
practitioner or specialist because of the concern of a caregiver who
notices memory and behavior differences. These patients typically
undergo a battery of low-cost and non-invasive neuropsychological
screenings, but provide only a subjective reference point with regard
to the symptomatic degree of cognitive decline. Considering that
irreversible neuronal damage occurs decades prior to the onset of
neurobehavioral and neuropsychiatric symptoms, the ability to lon-
gitudinally detect subtle changes to the cerebral parenchyma and
microvasculature are paramount for preclinical AD diagnosis. Table 1
outlines additional non-invasive and minimally invasive screening
methods that may be beneficial to the refinement of these AD
subgroups.
Genetic testing is a useful screening method for determining genes
associated with EOAD and LOAD, particularly in individuals with a
family history of AD. These are often inexpensive and some are avail-
able for in home genetic services. However, consideration is needed
with regard to the long-term psychological implications of knowing the
genetic predisposition for any disorder. Although genetic counseling
may be needed, an earlier diagnosis allows for implementation of risk-
reduction strategies.65 Once possible genetic markers have been elu-
cidated, additional clinical utilities can help determine environmental
AD subgroups. A patient history is useful for determining prior TBI and
possible microbial infiltration. Because CSF is in direct contact with
the brain, a lumbar puncture can be used to monitor plaque accumula-
tion (decreased Aβ42 CSF), neurofibrillary tangles (elevated phospho-
rylated tau CSF), and neuronal damage (elevated total tau CSF). When
coupledwith advances in neuroimaging techniques, this can lead to fur-
ther refinement for cerebral proteinopathy accumulation, neurovas-
cular changes, and glucose metabolism. Monitoring brain activity with
electroencephalography could elucidate regions with hyperactive neu-
ronal networks, while polysomnography can detect sleep disorders.
Unfortunately, these additional screening methods are both cumber-
some and expensive. Accordingly, blood or plasma biomarker determi-
nation is the sought-after solution, but this is potentially hindered by
age-associated changes to the blood proteome. Identification of spe-
cific microRNAsmay prove beneficial in subgroups with mitochondrial
dysfunction or senescent cell accumulation.
2 CONCLUSIONS
Despite decades of clinical trials, the AD field is not closer to bringing
disease-modifying therapeutics to market. To improve therapeutic
outcome for the rapidly growing AD population, an ideological shift
regarding the interpretation of AD is needed. The intention of this
TABLE 1 AD subgroup diagnostics determinants
AD subgroup Diagnostic determinates
Genetic
APP Genetic testing, amyloid positron emission
tomography, CSF amyloid levels
PS1/PS2 Genetic testing, amyloid positron emission
tomography, CSF amyloid levels
APOE ε4 Genetic testing, FDG-PET,
blood-oxygen-level dependent functional
magnetic resonance imaging, CSF lipid,
phosphorylated tau, and tau/Aβ42 levels
TOMM40 Genetic testing, microRNAs







Cellular senescence microRNAs, FDG-PET
Mitochondrial
dysfunction
TOMM40 genetic testing, electron
paramagnetic resonance imaging,
microRNAs
Metabolic syndrome Hemoglobin A1c levels, fasting blood
glucose, hypertension, FDG-PET,
blood-oxygen-level dependent functional
magnetic resonance imaging, microRNAs
Blood–brain barrier
disruption
Magnetic resonance imaging, arterial spin
labelingmagnetic resonance imaging,
blood-oxygen-level dependent functional
magnetic resonance imaging, dynamic




Prior history of concussions with loss of
consciousness, computerized
tomography, magnetic resonance imaging,
diffusion tensor imaging
Sleep disruption Polysomnography, CSF for Aβ/APP
clearance, actigraphy,
electroencephalography
Microbial infiltration Patient history, CSF
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E gene;
APP, amyloid precursor protein; CSF, cerebral spinal fluid; FDG-PET,
[18F]fluorodeoxyglucose positron emission tomography; PS1/2, presenilin
1 or 2; TOMM40, translocase of outer mitochondrial membrane 40 gene;
TREM2, triggering receptors expressed onmyeloid cells gene2.
article is to initiate a discussion regarding the multiple causalities that
culminate in the anterograde amnesia and cerebral atrophy that the
field has grouped into a single disease entity—AD. The idea of creating
subgroups allows for better identification of biomarkers across a
narrower patient population for improved pharmacotherapeutic
opportunities. These biomarkers can then aid in designing appropriate
preclinical models thatmore accurately recapitulate subgroup-specific
disease pathologies for identification and testing of novel therapeutics.
The interrelatedness of many of these proposed subgroups indicates
the complexity of this disorder as shown in Figure 1. However, it
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F IGURE 1 Overlapping genetic and environmental subgroups. Genetic screening for determination of early and late-onset AD subgroups can
identify individuals at risk for developing dementia before symptoms appear. Individuals who screen positive can implement life-style
risk-reduction strategies that are known to have long-term pro-cognitive benefits. In addition, annual positron emission tomography (PET)
monitoring for accumulation of proteinopathies may provide therapeutic opportunities for health-span and lifespan extensions in these at-risk
individuals.Without readily identifiable biomarkers, environmental factors aremore difficult to screen, thereby delaying a diagnoses until overt
signs of dementia are present. The environmental subgroups discussed are arranged adjacent to potentially overlapping pathologies. This
highlights environmental subgroups with possible comorbidities that may require multiple therapeutic strategies for individualized patient care.
Furthermore, genetic subgroup pathologies may exacerbate particular environmental subgroups as indicated by their inset symbol. AD,
Alzheimer’s disease; APOE, apolipoprotein E gene; APP, amyloid precursor protein; BBB, blood–brain barrier; MetS, metabolic syndrome; PS1/2,
presenilin 1 or 2; TBI, traumatic brain injury; TOMM40, translocase of outer mitochondrial membrane 40 gene; TREM2, triggering receptors
expressed onmyeloid cells 2 gene
also supports that no one single factor may initiate the cascade of
events culminating in neurodegeneration and cognitive decline. As
such, combination therapeutic approaches may be warranted. Finally,
longitudinal analysis as well as sexual dimorphisms associated with
each subgroup could further refine individualized treatment options.
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